1-4 of 4
Pierre Major
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Allan Lipton, Robert E. Coleman, Pierre Major, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang, Hei, Richard Cook
Journal: Blood
Blood (2005) 106 (11): 3456.
https://doi.org/10.1182/blood.V106.11.3456.3456
Published: 2005
Journal Articles

Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).

Richard J. Cook, Robert E. Coleman, Pierre Major, Allan Lipton, Janet E. Brown, Ker-Ai Lee, Matthew Smith, Fred Saad, YinMiao Chen, Yong Jiang Hei
Journal: Blood
Blood (2005) 106 (11): 5015.
https://doi.org/10.1182/blood.V106.11.5015.5015
Published: 2005
Journal Articles

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

James R. Berenson, Pierre Major, Regina A. Swift, Robert Vescio, Christina Rivera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran
Journal: Blood
Blood (2005) 106 (11): 5192.
https://doi.org/10.1182/blood.V106.11.5192.5192
Published: 2005
Journal Articles

The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.

James Berenson, Pierre Major, Christina Ravera, Sanela Bilic, Horst Schran
Journal: Blood
Blood (2004) 104 (11): 4939.
https://doi.org/10.1182/blood.V104.11.4939.4939
Published: 2004